GlaxoSmithKline may not sell Synflorix in the US

GlaxoSmithKline reported Thursday that it may not sell its paediatric pneumococcal vaccine Synflorix on the US market. The product, which is expected to compete with Wyeth's Prevnar, received a positive opinion from the EU in January but has not been submitted for regulatory approval in the US.

"It's clear that Synflorix versus Prevnar is a much more competitive innovation outside of the US because of the presence of different pneumococcal subtypes," noted CEO Andrew Witty, who added that although the drugmaker has not made a final decision, he believes the company is "more likely to tackle the US with a different type of vaccine to Synflorix." GlaxoSmithKline's vaccine is designed to protect against 10 strains of streptococcus pneumoniae, while Wyeth's vaccine protects against seven strains.

To read more Top Story articles, click here.